ALSUntangled 48: Perampanel (Fycompa)

References

• http://www.alsuntangled.com/open.php. Accessed December 11, 2018. Archived by WebCite® at http://www.webcitation.org/74bHIlKSA.
   Google Scholar
• Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018;137:378–91.
   Google Scholar
• Blasco H, Mavel S, Corcia P, Gordon P. The glutamate hypothesis in ALS: pathophysiology and drug development. Curr Med Chem. 2014;21:3551–75.
   Google Scholar
• Yamashita T, Kwak S. Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. Neurosci Res. 2018; [Epub ahead of print].
   Google Scholar
• Spalloni A, Albo F, Ferrari F, Mercuri N, Bernardi G, Zona C, et al. Cu/Zn-superoxide dismutase (GLY93->ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate mediated toxicity in motor neurons in culture. Neurobiol Dis. 2004;15:340–50.
   Google Scholar
• Selvaraj B, Livesey M, Zhao C, Gregory J, James O, Cleary EM, et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptormediated excitotoxicity. Nat Commun. 2018;9:347.
   Google Scholar
• Aizawa H, Hideyama T, Yamashita T, Kimura T, Suzuki N, Aoki M, et al. Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUS(P525L) mutation. J Clin Neurosci. 2016;32:128–9.
   Google Scholar
• Udagawa T, Fujioka Y, Tanaka M, Honda D, Yokoi S, et al. FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nat Commun. 2015;6:7098.
   Google Scholar
• Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Burnashev N, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406:78–81.
   Google Scholar
• Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30:11917–25.
   Google Scholar
• Hibi S, Ueno K, Nagato S, Kawano K, Ito K, Norimine Y, et al. Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med Chem. 2012;55:10584–600.
   Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331–40.
   Google Scholar
• Barygin O. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons. Neurosci Lett. 2016;633:146–51.
   Google Scholar
• Chen C, Matt L, Hell J, Rogawski M. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014;9:e108021.
   Google Scholar
• Ceolin L, Bortolotto Z, Bannister N, Collingridge G, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61:517–22.
   Google Scholar
• Rogawski M, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand. 2013;127:19–24.
   Google Scholar
• Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;3:CD001447.
   Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456–64.
   Google Scholar
• Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
   Google Scholar
• https://ir.tevapharm.com/investors/press-releases/press-release-details/2010/Teva-Provides-Update-on-Talampanel-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS/default.aspx. Accessed December 16, 2018. Archived by WebCite® at http://www.webcitation.org/74iBnIiir.
   Google Scholar
• Bellingham M. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Therap. 2011;17:4–31.
   Google Scholar
• White H. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache. 2005;45:S48–S56.
   Google Scholar
• Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–7.
   Google Scholar
• Wang C, Niu L. Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives. ACS Chem Neurosci. 2013;4:635–44.
   Google Scholar
• Elger B, Huth A, Neuhaus R, Ottow E, Schneider H, Seilheimer B, et al. Novel α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration. J Med Chem. 2005;48:4618–27.
   Google Scholar
• Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. PNAS. 1993;90:6591–5.
   Google Scholar
• Tortarolo M, Grignaschi G, Calvaresi N, Zennaro E, Spaltro G, Colovic M, et al. Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J Neurosci Res. 2006;83:134–46.
   Google Scholar
• Paizs M, Tortarolo M, Bendotti C, Engelhardt J, Siklos L. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011;12:340–4.
   Google Scholar
• Canton T, Bohme G, Boireau A, Bordier F, Mignani S, Jimonet P, et al. RPR 119990, a novel α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2001;299:314–22.
   Google Scholar
• Parsons C, Gruner R, Rozental J. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methylendioxyl-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology. 1994;33:589–604.
   Google Scholar
• Dammae P, Leyssen M, Callewaert G, Robberecht W, van den Bosch L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett. 2003;343:81–4.
   Google Scholar
• Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307.
   Google Scholar
• Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120:75–84.
   Google Scholar
• Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649.
   Google Scholar
• Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J-P, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
   Google Scholar
• https://www.patientslikeme.com/conditions/als. Accessed December 16, 2018.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03020797. Accessed December 16, 2018. Archived by WebCite® at http://www.webcitation.org/74iA29RXr.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03019419. Accessed December 16, 2018. Archived by WebCite® at http://www.webcitation.org/74iACNIuE.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03377309. Accessed December 16, 2018. Archived by WebCite® at http://www.webcitation.org/74iALI2Ut.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03793868. Accessed January 14, 2019. Archived by WebCite® at http://www.webcitation.org/75QHKY4EJ.
   Google Scholar
• Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266–71.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/study/NCT00696332. Accessed December 16, 2018. Archived by WebCite® at http://www.webcitation.org/74iC1Z1xU.
   Google Scholar
• Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55:13–5.
   Google Scholar
• Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson’s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733–40.
   Google Scholar
• Fycompa [package insert]. Woodcliff Lake, NJ: Eisai Inc.; September 2018. Archived by WebCite® at http://www.webcitation.org/75QKfQLAr.
   Google Scholar
• Wu C, McShane M, Huttlin E, Novoa K. Severe aggression after perampanel overdose: case report. Psychosomatics. 2018; [Epub ahead of print].
   Google Scholar
• Rabkin J, Goetz R, Murphy J, Factor-Litvak P, Mitsumoto H, ALS COSMOS Study Group. Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort. Neurology. 2016;87:1320–8.
   Google Scholar
• Bock M, Duong Y, Kim A, Allen I, Murphy J, Lomen-Hoerth C. Cognitive-behavioral changes in amyotrophic lateral sclerosis: screening prevalence and impact on patients and caregivers. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:366–73.
   Google Scholar
• Lillo P, Mioshi E, Zoing M, Kiernan M, Hodges J. How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2011;12:45–51.
   Google Scholar
• https://www.goodrx.com/perampanel?dosage=4mg&form=tablet&quantity=30. Accessed December 16, 2018.
   Google Scholar
• https://www.goodrx.com/perampanel?dosage=8mg&form=tablet&quantity=30. Accessed December 16, 2018.
   Google Scholar